The clinical efficacy of neoantigen-reactive TILs or TCR-T therapy is primarily attributed to the effective CD8+ T cell responses that appear to target predominantly tumor-specific antigens exposed by HLA-I on the cell surface [14,15]. Here, CD8A is linked to neoplasm.